

SUPPORT FOR THE AMENDMENTS

Claim 1 has been amended.

The amendment of Claim 1 is supported by the Examples presented in the specification.

No new matter has been added by the present amendments.

REMARKS

Claims 1-15 are pending in the present application.

The rejection of Claims 1-10 under 35 U.S.C. §112, first paragraph (written description and enablement), is obviated by amendment.

Applicants have amended the claims to specify that the oligomeric protein is CHH-B protein, which the Examiner appears to recognize as being adequately described and enabled. To further support the description and enablement of the claims as amended the Examiner's attention is referred to the Examples of the present specification.

Applicants request withdrawal of these grounds of rejection.

The objections to the specification are obviated in part by amendment and traversed in part.

Applicants have amended the paragraph beginning at page 1, line 10 to address the Examiner's specific criticism. Therefore, this criticism is now believed to be moot.

With respect to the Examiner's objection to Figure 6, Applicants respectfully traverse the Examiner's objection. In the response filed on July 17, 2006, Applicants made the following amendment to the Brief Description of the Drawings:

Please amend the paragraph beginning on page 10, line 3 as follows:

Fig. 6 Fig. 6a is a reverse phase liquid chromatogram of the AS1051 protein in which the cysteine residue at position 81 was replaced with an alanine residue (AS1051-Ala) after digestion with lysyl endopeptidase. Fig. 6b is a reverse phase liquid chromatogram of the polyethylene-glycolated AS1051 (AS1051-PEG) after digestion with lysyl endopeptidase. The polypeptide fragments in Fig. 6 can be found in the Sequence Listing as follows: sequence 1 = residues 41-43 of SEQ ID NO: 5; sequence 2 = residues 145-149 of SEQ ID NO: 5; sequence 3 = residues 24-40 of SEQ ID NO: 5; sequence 4 (top) = residues 85-100 of SEQ ID NO: 5 and sequence 4 (bottom) = residues 44-60 of SEQ ID NO: 5; sequence 5 (top) = residues 133-144 of

SEQ ID NO: 5 and sequence 5 (bottom) = residues 101-132 of SEQ ID NO: 5;  
sequence 6 = residues 61-84 of SEQ ID NO: 5.

MPEP §2422.02 states “the sequence must still be included in the Sequence Listing and the sequence identifier (“SEQ ID NO:X”) must be used, *either in the drawing or in the Brief Description of the Drawings.*” (emphasis added) Therefore, the amendment to the Brief Description of the Drawings filed on July 17, 2006, is proper and the present specification is in compliance with the Sequence Listing rules.

Withdrawal of this ground of objection is requested.

Applicants submit that the present application is now in condition for allowance.  
Early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Stephen G. Baxter, Ph.D.  
Registration No. 32,884

Vincent K. Shier, Ph.D.  
Registration No. 50,552

Customer Number

**22850**

Tel: (703) 413-3000  
Fax: (703) 413-2220  
(OSMMN 08/03)